



November 20, 2023

Dear Wake Up Narcolepsy Community and Monica,

With today's announcement of the completion of Zevra's acquisition of Acer Therapeutics, we want to take this opportunity to reassure you of our commitment to people affected by rare sleep disorders and Wake Up Narcolepsy. At Zevra, our mission is to give every promising rare disease therapy candidate a fighting chance to reach patients and improve their quality of life, and we value your partnership in helping to make this vision a reality.

We remain committed to the continued development of KP1077 as a much-needed therapy for the treatment of idiopathic hypersomnia (IH) and narcolepsy. We recently announced our interim results of our Phase 2 trial for KP1077 demonstrating it is well-tolerated at all dose levels and both dosing regimens included in the study. We look forward to reporting topline Phase 2 results in the first half of 2024. You can read more about KP1077 and the interim data announcement [here](#).

As a newly combined company, we have expanded our already strong foundation and added capabilities that will help advance our programs for rare diseases, including sleep disorders, Niemann-Pick disease type C (NPC), urea cycle disorders (UCDs) and Vascular Ehlers-Danlos syndrome (VEDS).

We are grateful for the work we've done together and are proud to be your partner as we work toward our shared goal of bringing a much-needed potential therapy to people living with sleep disorders, including IH and narcolepsy. You can learn more about our advocacy programs here on the [Zevra](#) and [Acer](#) websites.

Sincerely,  
The Zevra Team